[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630873":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":34,"centralContacts":44,"locations":34,"responsibleParty":53,"collaborators":34,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":34,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":34,"enrollmentInfo":66,"targetDuration":34,"studyType":69,"phases":70,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":80,"whyStopped":34,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":34},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Zeprumetostat+Azacitadine (if with TET2 plus RHOA gene mutation)","EXPERIMENTAL","Zeprumetostat: 350 mg bid, orally, till disease progression (PD) or unacceptable toxicity. Azacitadine :100mg D1-D7, subcutaneous injection, should ≥2 out of 6 pts experience a DLT, the dose will be adjusted to: Azacitidine 100 mg D1-D5, subcutaneous injection for total 3 cycles.",[13],"Drug: Zeprumetostat+Azacitadine",{"label":15,"type":10,"description":16,"interventionNames":17},"Zeprumetostat+Decitabine (if with TP53 gene mutation)","Zeprumetostat: 350 mg bid, orally, till disease progression (PD) or unacceptable toxicity. Decitabine 10mg\u002Fm2 D1-D5, intravenous infusion, should ≥2 out of 6 pts experience a DLT, the dose will be adjusted to: Decitabine 10mg\u002Fm2 D1-D3 for total 3 cycles.",[18],"Drug: Zeprumetostat+Chidamide",{"label":20,"type":10,"description":21,"interventionNames":22},"Zeprumetostat+Chidamide (if with CREBBP\u002FEP300\u002FKMT2C\u002FKMT2D\u002FNCOR2 gene mutation)","Zeprumetostat: 350 mg bid, orally, till disease progression (PD) or unacceptable toxicity. Chidamide 30 mg biw orally, should ≥2 out of 6 pts experience a DLT, the dose will be adjusted to: Chidamide 20 mg biw for total 3 cycles.",[23],"Drug: Zeprumetostat+Decitabine",{"label":25,"type":10,"description":26,"interventionNames":27},"Zeprumetostat+Golidocitinib (if not above genotype)","Zeprumetostat: 350 mg bid, orally, till disease progression (PD) or unacceptable toxicity. Golidocitinib 150 mg qd orally, should ≥2 out of 6 pts experience a DLT, the dose will be adjusted to: Golidocitinib 150 mg qod for total 3 cycles.",[28],"Drug: Zeprumetostat+Golidocitinib",[30,35,38,41],{"type":31,"name":32,"description":11,"armGroupLabels":33,"otherNames":34},"DRUG","Zeprumetostat+Azacitadine",[9],null,{"type":31,"name":36,"description":16,"armGroupLabels":37,"otherNames":34},"Zeprumetostat+Decitabine",[20],{"type":31,"name":39,"description":21,"armGroupLabels":40,"otherNames":34},"Zeprumetostat+Chidamide",[15],{"type":31,"name":42,"description":26,"armGroupLabels":43,"otherNames":34},"Zeprumetostat+Golidocitinib",[25],[45,50],{"name":46,"role":47,"phone":48,"phoneExt":34,"email":49},"Weili Zhao","CONTACT","086-022-64370045","zwl_trial@163.com",{"name":51,"role":47,"phone":34,"phoneExt":34,"email":52},"Pengpeng Xu","pengpeng_xu@126.com",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":34,"oldOrganization":34},"PRINCIPAL_INVESTIGATOR","Zhao Weili","Vice president of Ruijin Hospital","100630873","phase-1-genotype-guided-targeted-agents-plus-ezh2i-for-primary-refractory-ptcl-100630873",false,"NCT07493330","Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL","Genotype-guided Targeted Agents in Combination With EZH2 Inhibitor, Zeprumetostat for Primary Refractory Peripheral T-cell Lymphoma (PTCL), a Prospective, Open-label, Multi-center Study","Inclusion Criteria:\n\n* Age ≥ 18 years, male or female.\n* Patients with a histopathologically confirmed diagnosis of peripheral T-cell lymphoma (PTCL) based on 2016 WHO classification\n* Previously treated with 3 or 6 cycles of a CHOP-like regimen as first-line therapy and considered primary refractory. Patients with anaplastic large cell lymphoma (ALCL) must have adequately received brentuximab vedotin (BV) as part of their first-line treatment.\n* Tumor tissue genotyping performed and results available prior to enrollment.\n* ECOG 0, 1, or 2.\n* Life expectancy greater than 3 months.\n* Adequate organ function\n* Contraception during study\n* Informed consented\n\nExclusion Criteria:\n\n* Has a prior malignancy other than the malignancies under study within 3 years without relieve\n* Primary CNS lymphoma\n* Known hypersensitivity to any study drug.\n* Pregnant or lactation\n* Active infection.\n* Diseases and medical history:\n\n  1. Requires continuous treatment with strong or moderate CYP3A inhibitors or CYP3A inducers\n  2. Has multiple factors affecting oral medication administration (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, etc.);\n  3. Has a history of psychoactive substance abuse that cannot be discontinued\n  4. Has any severe and\u002For uncontrolled disease.\n* Uncontrollable autoimmune disease,\n* Not able to comply to the protocol for mental or other unknown reasons\n* Any other condition that, in the investigator's judgment, makes the patient unsuitable for study participation.","ALL","18 Years",{"count":67,"type":68},86,"ESTIMATED","INTERVENTIONAL",[71,72],"PHASE1","PHASE2","To evaluate the safety and efficacy of Zeprumetostat-based combination therapy, selected according to genotyping results, in patients with primary refractory peripheral T-cell lymphoma (PTCL).",[75,76],"PTCL","Refractory",[75,78,79,76],"Genotype-guided","Zeprumetostat","NOT_YET_RECRUITING","2026-04-01",{"date":83,"type":84},"2026-04-07","ACTUAL",{"date":86,"type":68},"2026-03-23",{"date":88,"type":68},"2030-12-12",{"name":5,"class":6}]